Charles Schwab’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-380,042
| Closed | -$4.97M | – | 3462 |
|
|
2025
Q4 | $4.97M | Buy |
380,042
+50,820
| +15% | +$607K | ﹤0.01% | 2459 |
|
|
2025
Q3 | $2.4M | Buy |
329,222
+18,642
| +6% | +$126K | ﹤0.01% | 2707 |
|
|
2025
Q2 | $1.66M | Sell |
310,580
-4,436
| -1% | -$21.5K | ﹤0.01% | 2726 |
|
|
2025
Q1 | $1.68M | Sell |
315,016
-7,560
| -2% | -$52.9K | ﹤0.01% | 2667 |
|
|
2024
Q4 | $2.88M | Buy |
322,576
+8,311
| +3% | +$88.3K | ﹤0.01% | 2560 |
|
|
2024
Q3 | $3.46M | Buy |
314,265
+189,727
| +152% | +$2.11M | ﹤0.01% | 2538 |
|
|
2024
Q2 | $1.13M | Sell |
124,538
-6,531
| -5% | -$63.8K | ﹤0.01% | 2886 |
|
|
2024
Q1 | $1.84M | Buy |
131,069
+44,287
| +51% | +$552K | ﹤0.01% | 2618 |
|
|
2023
Q4 | $666K | Buy |
86,782
+18,558
| +27% | +$103K | ﹤0.01% | 2970 |
|
|
2023
Q3 | $509K | Hold |
68,224
| – | – | ﹤0.01% | 3032 |
|
|
2023
Q2 | $568K | Buy |
+68,224
| New | +$787K | ﹤0.01% | 2991 |
|
|
2021
Q2 | – | Sell |
-7,602
| Closed | -$132K | – | 3416 |
|
|
2021
Q1 | $132K | Sell |
7,602
-1,206
| -14% | -$21.8K | ﹤0.01% | 3358 |
|
|
2020
Q4 | $114K | Hold |
8,808
| – | – | ﹤0.01% | 3313 |
|
|
2020
Q3 | $328K | Hold |
8,808
| – | – | ﹤0.01% | 3003 |
|
|
2020
Q2 | $340K | Buy |
+8,808
| New | +$314K | ﹤0.01% | 2984 |
|
Charles Schwab's ATXS Position: Q1 2026 in Review
Charles Schwab sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 380,042 shares — an estimated $4.97M sold.
Charles Schwab first reported a position in ATXS in Q2 2020 and held it in 15 quarters. The position peaked at $4.97M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Charles Schwab reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Charles Schwab sold 380,042 Astria Therapeutics shares in Q1 2026, an estimated $4.97M.
- Charles Schwab first reported a position in Astria Therapeutics in Q2 2020 and held it in 15 quarters.
- Charles Schwab's Astria Therapeutics position peaked at $4.97M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.